Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GT919 plus dexamethasone in relapsed or refractory POEMS syndrome
CTR20253208Phase 2Active
- Sponsor
- Gluetacs Therapeutics
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GT919, dexamethasone in osteosclerotic myeloma (POEMS), sponsored by Gluetacs Therapeutics. Started Dec 2025; status: active.
02
Drugs
GT919dexamethasone
03
Conditions
osteosclerotic myeloma (POEMS)
Beyond the preview
Go deeper on CTR20253208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253208.